Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952323 | 0.79 | GSK3B (0.51) | GSK3BMETAP2CYP2A6PIM3PTGES | |
| SCHEMBL14339329 | 0.77 | KDM4E (0.50) | PARP1CA12CA9 | |
| SCHEMBL22128321 | 0.72 | GSK3B (0.51) | GSK3BMETAP2CYP2A6PIM3PIM1 | |
| SCHEMBL20625430 | 0.72 | DAO (0.48) | PARP1 | |
| SCHEMBL10153752 | 0.71 | PARP1 (0.56) | GSK3BMETAP2PIM3PTGESCYP3A4 | |
| SCHEMBL26596718 | 0.70 | GPR17 (0.36) | — | |
| SCHEMBL16920112 | 0.69 | PIM1 (0.46) | GSK3BCYP2A6PIM3CYP2C9CYP2C19 | |
| SCHEMBL29951828 | 0.69 | PIM1 (0.46) | GSK3BCYP2A6PIM3CYP2C9CYP2C19 | |
| SCHEMBL29951207 | 0.69 | GSK3B (0.48) | GSK3BMETAP2CYP2A6PIM3PIM1 | |
| SCHEMBL29171685 | 0.68 | TP53 (0.47) | GSK3BMETAP2PIM3PTGESCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103012397-B | Pyrazolo (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide, its preparation method and its therapeutic use | 赛诺菲 | 2017-03-01 | — | — | CN | disclosed |
| EP-2760841-B1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-9169246-B2 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-10-27 | — | — | US | disclosed |
| EP-2573073-B1 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-21 | — | — | US | disclosed |
| EP-2760841-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045400-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-04 | — | — | WO | disclosed |
| CN-103012397-A | Pyrazolo quinolinone derivative and preparation method thereof as well as therapeutic application of derivative | SAI NUOFEI | 2013-04-03 | — | — | CN | disclosed |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| EP-2573073-A1 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, COQ8A, CYP1A2 | GSK3B 2801/4885METAP2 3886/4885CYP2A6 469/4885 |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP1A2, COQ8A | GSK3B 2668/4885METAP2 4100/4885CYP2A6 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.